Study guide

5.4 Medications, OTC Products, Supplements & Substances: Effects on Sleep

Certification in Clinical Sleep Health CCSH

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Sleep Physiology

1.1 CCSH Exam Overview & Clinical Scope 1.2 Sleep Architecture, Stages & Normal Cycles 1.3 Neurobiology & The Two-Process Model of Sleep

2 Chapter 2: Circadian Biology, Lifespan & Normal Variation

2.1 Circadian Biology & Melatonin Regulation 2.2 Sleep Across the Lifespan: Pediatric to Geriatric 2.3 Sex, Gender, Environment & Culture: Variations in Normal Sleep

3 Chapter 3: Abnormal Sleep: Classification, Prevalence & Consequences

3.1 Classification, Terminology, Prevalence & Acute vs. Chronic Sleep Disturbances 3.2 Short- and Long-Term Effects of Sleep Disruption, Deprivation & Restriction

4 Chapter 4: Comorbid Medical & Mental Health Conditions

4.1 Cardiopulmonary, Metabolic & Neurological Comorbidities 4.2 Mental Health Disorders, Substance Use & Sleep 4.3 Chronic Pain & Other Medical Conditions Affecting Sleep

5 Chapter 5: Clinical Assessment, Documentation & Medications

5.1 Validated Questionnaires & Screening Instruments 5.2 Comprehensive Sleep History & Physical Assessment 5.3 Quality of Life, Health Changes & Clinical Documentation 5.4 Medications, OTC Products, Supplements & Substances: Effects on Sleep

6 Chapter 6: Sleep Testing & Explaining Results

6.1 Diagnostic Sleep Testing Modalities 6.2 Split-Night and Titration Studies, PAP-NAP, Oximetry & Explaining Results

7 Chapter 7: Sleep-Related Breathing Disorders

7.1 Obstructive Sleep Apnea: Pathophysiology & Diagnosis 7.2 Central Sleep Apnea, Cheyne-Stokes & Emergent Apneas 7.3 Sleep-Related Hypoventilation & Obesity Hypoventilation Syndrome

8 Chapter 8: Positive Airway Pressure Therapy & Titration

8.1 Modes of PAP Therapy: CPAP, APAP, BiPAP & ASV 8.2 Interfaces, Humidification & Equipment Troubleshooting 8.3 Objective PAP Adherence Monitoring & Troubleshooting

9 Chapter 9: Non-PAP Treatments for Sleep Apnea

9.1 Oral Appliance Therapy: Indications, Candidacy & Side Effects 9.2 Surgical Interventions & Hypoglossal Nerve Stimulation 9.3 Positional Therapy & Lifestyle Modifications

10 Chapter 10: Insomnia & Circadian Rhythm Sleep-Wake Disorders

10.1 Chronic Insomnia: ICSD-3 Classification & Assessment 10.2 Cognitive Behavioral Therapy for Insomnia (CBT-I) Principles 10.3 Circadian Rhythm Sleep-Wake Disorders & Light Therapy

11 Chapter 11: Hypersomnias, Parasomnias & Movement Disorders

11.1 Central Disorders of Hypersomnolence 11.2 Parasomnias: NREM & REM Sleep Behavior Disorders 11.3 Sleep-Related Movement Disorders: RLS & PLMD

12 Chapter 12: Patient, Family & Community Education

12.1 Health Literacy, Plain Language & Teach-Back 12.2 Cultural Competency, Diversity of the Learner & Language Access 12.3 Readiness to Learn & Teaching Across Age, Development and Role 12.4 Learning Styles, Adult Learning Principles & Teaching Methods 12.5 Communication Barriers, Disabilities & Educating Families, Professionals and the Community

13 Chapter 13: Self-Management & Behavior Change

13.1 Motivational Interviewing & Overcoming Treatment Barriers 13.2 Sleep Hygiene Education Across Lifestyles and Settings 13.3 Self-Assessment & Self-Management Tools 13.4 Commercial Drivers, Transportation Regulations & Drowsy Driving

14 Chapter 14: Care Coordination, Guidelines, Telehealth & Ethics

14.1 Interdisciplinary Care Coordination & Patient Navigation 14.2 Chronic Disease Model, Care Plans & AASM Clinical Practice Guidelines 14.3 Telehealth Modalities & Remote Patient Monitoring 14.4 Ethics, Scope of Practice & Legal Standards

15 Chapter 15: Program Administration, Public Health & Safety

15.1 Building Collaborative Sleep Programs: Perioperative, Occupational, Outpatient & Support Models 15.2 Quality Improvement, Clinical Outcomes & Accreditation Standards 15.3 Sleep as a Public Health Issue: Community Outreach & Public Policy 15.4 Clinical Safety, Infection Control & Emergency Protocols

5.4 Medications, OTC Products, Supplements & Substances: Effects on Sleep

Key Takeaways Explain This Topic AI

Medication reconciliation in a sleep clinic includes prescriptions, OTC products, supplements, caffeine, alcohol, nicotine and cannabis, with doses and timing.

SSRIs and SNRIs can suppress REM, cause insomnia or vivid dreams, and worsen restless legs and periodic limb movements; beta-blockers can reduce melatonin and disturb sleep.

First-generation antihistamines such as diphenhydramine are on the AGS Beers Criteria list of drugs to avoid in older adults.

U.S. melatonin is sold as a dietary supplement, and tested products contained 74–347% of the labeled amount in one 2023 study of gummies.

Opioids, benzodiazepines, gabapentinoids and alcohol suppress breathing; the CCSH reports risky combinations to the prescriber but never changes medications.

Last updated: October 2026

5.4 Medications, OTC Products, Supplements & Substances: Effects on Sleep

The blueprint lists medications, over-the-counter products and supplements as knowledge areas and asks the CCSH to evaluate the impact of medications (prescription, OTC, supplements) during history taking. Many sleep complaints are side effects, and some drug combinations are dangerous for people with sleep apnea.

Medication Reconciliation in a Sleep Clinic

A complete list includes:

  • prescription drugs, with dose and time of day ;
  • OTC products (sleep aids, decongestants, pain relievers, antacids);
  • dietary supplements and herbal products (melatonin, valerian, magnesium, CBD);
  • caffeine sources, alcohol, nicotine, cannabis and other substances; and

recent starts, stops and dose changes (withdrawal also affects sleep and testing).

Ask open questions ("What do you take to help you sleep?" and "What do you take to stay awake?") and use the brown-bag method (patients bring all products) when possible.

Prescription Drugs That Affect Sleep

Drug class Common sleep effects

SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine) Insomnia or sedation, REM suppression, vivid dreams, REM sleep without atonia, worsened RLS/PLMS, bruxism

  • Tricyclic antidepressants Sedation, REM suppression, anticholinergic effects, worsened RLS
  • Mirtazapine, trazodone Sedation, next-day grogginess; mirtazapine causes weight gain and can worsen RLS
  • Bupropion Activating; insomnia; does not usually worsen RLS
  • Beta-blockers (propranolol, metoprolol) Lower nighttime melatonin; insomnia and vivid dreams or nightmares
  • Corticosteroids Insomnia, especially with evening doses; weight gain
  • Diuretics Nocturia if taken late in the day
  • Stimulants and wake-promoting drugs Insomnia if taken late; affect MSLT results
  • Antipsychotics Sedation, weight gain (raising OSA risk), restlessness that mimics RLS
  • Dopamine agonists Sudden sleep episodes, RLS augmentation, impulse-control problems
  • Theophylline, levothyroxine excess, decongestants Insomnia and arousal
  • Drugs That Affect Breathing During Sleep

Opioids: central sleep apnea, ataxic breathing and hypoventilation; they also worsen OSA.

Benzodiazepines and Z-drugs: relax airway muscles and blunt arousal; the FDA requires a boxed warning when opioids are combined with benzodiazepines, and Z-drugs carry a boxed warning for complex sleep behaviors such as sleep-driving. In 2013 the FDA lowered the recommended starting dose of zolpidem for women because of next-morning impairment.

Gabapentinoids (gabapentin, pregabalin): sedation; the FDA warned in 2019 about serious breathing problems when they are combined with opioids or other sedatives or used by people with respiratory risk factors.

Alcohol: adds to all of the above.

Drugs That Affect Sleep Testing

REM-suppressing, alerting and sedating drugs alter MSLT results, which is why the prescriber may stop them about 2 weeks before testing. The CCSH reminds patients of these instructions but never stops a drug on their own.

Over-the-Counter Sleep Aids

Most OTC "PM" products contain diphenhydramine or doxylamine , first-generation antihistamines. They cause next-day drowsiness, confusion, constipation, urinary retention and dry mouth, and they can worsen restless legs. The American Geriatrics Society Beers Criteria list first-generation antihistamines as drugs to avoid in older adults, and the AASM's 2017 insomnia guideline recommends against diphenhydramine for chronic insomnia.

Dietary Supplements

In the United States, supplements are not approved by the FDA for safety and effectiveness before sale, and label accuracy varies.

Product What the evidence shows Cautions

Melatonin Useful when timed for circadian rhythm disorders and jet lag; small effects on sleep latency; the AASM recommends against it for chronic insomnia Content varies widely: a 2023 study of U.S. melatonin gummies found 74–347% of the labeled amount; pediatric melatonin ingestions reported to poison centers rose sharply over the last decade; look for third-party quality marks (such as USP Verified)

  • Valerian Weak evidence; the AASM recommends against it for chronic insomnia Rare liver injury reports
  • Kava Some anxiety benefit FDA advisory about severe liver injury
  • Magnesium Limited evidence for sleep Diarrhea; caution in kidney disease

L-tryptophan The AASM recommends against it for chronic insomnia Historic contamination outbreak (eosinophilia-myalgia syndrome)

CBD and cannabis products Only one prescription CBD product is FDA-approved, for certain seizure disorders; sleep evidence is limited Unregulated content, drowsiness, liver enzyme changes, drug interactions

St. John's wort Used for low mood Induces liver enzymes and reduces the effect of many drugs, including hormonal contraceptives

Energy drinks and caffeine pills Can contain 200 mg or more of caffeine per serving The FDA considers up to about 400 mg/day generally safe for healthy adults; more causes insomnia and palpitations

The CCSH's Role and Scope

Reconcile all products and their timing at intake and follow-up.

Recognize likely medication causes of insomnia, sleepiness, nightmares, RLS, nocturia or central apnea.

Report concerns and dangerous combinations (for example, opioids plus benzodiazepines in a patient with untreated OSA) to the prescriber, documenting the communication.

Educate patients on timing and safety (no alcohol with sedatives, avoid driving if drowsy) and on what the prescriber has decided.

Collaborate with pharmacists, who are valuable partners for interaction checks.

The CCSH does not start, stop or change doses. Changing a medication's timing is also the prescriber's decision.

Worked Example: What a Reconciliation Can Reveal

A 58-year-old man referred for "insomnia and fatigue" brings his medicines to the visit.

Finding Possible sleep effect Action

Metoprolol taken at 9 PM Lower melatonin; vivid dreams Report to the prescriber, who may consider a different time or drug

Fluoxetine started 2 months ago Insomnia, vivid dreams, worse leg restlessness Report the timing to the prescriber; note for any planned MSLT

  • Prednisone burst taken in the evening Insomnia Ask whether the dose can be given in the morning
  • OTC "PM" product nightly Next-day grogginess, worse RLS, confusion risk Educate; report use
  • Two energy drinks after 3 PM High caffeine late in the day Set a caffeine cutoff goal

Melatonin 10 mg at random times Poorly timed; dose content uncertain Discuss timing and quality with the clinician

Several "insomnia" causes are reversible here. Documenting them clearly and communicating with the prescriber can resolve the complaint without adding another sleep medicine.